Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
An erratum to this article was published (Diabetes Technol Ther, Aug 2026 ↗)
Pooled result · HbA1cResult — go to the resultWMD −0.31 % 95% CI −0.42 to −0.21Authors' conclusion
In this meta-analysis, rt-CGM and is-CGM were associated with improvement in glycemic control in people with T2D not using insulin when compared to SMBG.
Study context
- Population
- Noninsulin-treated people with T2D; diabetes duration 5.4 to 13.9 years, mean age 57.9 years, mean BMI 30.8 kg/m²
- Participants
- 407 people6 randomized controlled trials (RCTs)
- Comparison
- Continuous glucose monitoring (CGM) vs self-monitoring of blood glucose (SMBG)
- CGMn = 228
- Outcome
- HbA1c
Pooled result
As reported in the abstract
WMD
−0.31 %
95% CI −0.42 to −0.21
CGMvs SMBG
WMD −0.31 % (95% CI −0.42 to −0.21)
Further pooled results
| Outcome | WMD (mg/dL) (95% CI) | |
|---|---|---|
| Glucose levelI2 = 0% | −11.16 (−19.94 to −2.39) | |
| SD of glucose variationI2 = 0% | −4.00 (−6.86 to −1.14) | |
| −20−10010Difference, mg/dL (linear scale) |
| Outcome | WMD (%) (95% CI) | |
|---|---|---|
| Time in hypoglycemia level 2I2 = 91% | −0.28 (−0.52 to −0.03) | |
| Glucose time >180 mg/dLI2 = 0% | −7.75 (−12.04 to −3.45) | |
| TIRI2 = 0% | 8.63 (4.54–12.71) | |
| −20−1001020Difference, % (linear scale) |
| Outcome | SMD (95% CI) | |
|---|---|---|
| Treatment satisfactionI2 = 0% | 0.79 (0.54–1.05) | |
| −0.500.511.5Difference (linear scale) |
Original publication
Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Technol Ther. Published 13 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →